✦ LIBER ✦

TCT-404: Late Safety and Efficacy of a Zotarolimus-Eluting Stent Compared with a Paclitaxel-Eluting Stent in Patients with De Novo Coronary Lesions: Three-Year Follow-up from the ENDEAVOR IV Trial

Book ID: 113446556
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 228 KB
Volume: 104
Category: Article
ISSN: 0002-9149
DOI: 10.1016/j.amjcard.2009.08.430

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved Late Clinical Safety With Zotar

Improved Late Clinical Safety With Zotarolimus-Eluting Stents Compared With Paclitaxel-Eluting Stents in Patients With De Novo Coronary Lesions: 3-Year Follow-Up From the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) Trial

✍ Martin B. Leon; Eugenia Nikolsky; Donald E. Cutlip; Laura Mauri; Henry Liberman; 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 557 KB

TCT-24: The “Final” Five-Year Follow-up

TCT-24: The “Final” Five-Year Follow-up from the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent with a Paclitaxel-Eluting Stent

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 274 KB

The “Final” 5-Year Follow-Up From the EN

The “Final” 5-Year Follow-Up From the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent With a Paclitaxel-Eluting Stent

✍ Kirtane, Ajay J.; Leon, Martin B.; Ball, Michael W.; Bajwa, Harpaul S.; Sketch, 📂 Article 📅 2013 🏛 American College of Cardiology 🌐 English ⚖ 487 KB

A Randomized Comparison of the Endeavor

A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions: 12-Month Outcomes From the ENDEAVOR IV Trial

✍ Martin B. Leon; Laura Mauri; Jeffrey J. Popma; Donald E. Cutlip; Eugenia Nikolsk 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 923 KB

Late-Term Clinical Outcomes With Zotarol

Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)

✍ David E. Kandzari; Laura Mauri; Jeffrey J. Popma; Mark A. Turco; Paul A. Gurbel; 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 704 KB

A randomized, controlled, multi-center t

A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: Final results of the ZoMaxx II trial

✍ William A. Gray; Alan C. Yeung; Donald E. Cutlip; Jeffrey J. Popma; Peter J. Fit 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 382 KB